Buprenorphine and naloxone market size?

Buprenorphine + naloxone (often sold as the combination buprenorphine/naloxone for opioid use disorder, e.g., Suboxone® and generics) is a large and growing market. However, “market size” depends heavily on whether you mean:

1. Global revenue (USD) for the branded/generic combination products
2. Unit volume (e.g., tablets/films)
3. Which geography (US only vs global)
4. Whether you include all buprenorphine/naloxone formulations (films, tablets) and all payers (retail + institutional/covered claims)

What I can do for you

If you tell me (a) geography (global or US), (b) year (e.g., 2023/2024/2025), and (c) market definition (revenue vs units, retail vs total), I can give you the most relevant estimate and cite the typical industry sources used for this category.

Quick directional context (not exact figures)

• In the US, buprenorphine/naloxone is one of the dominant medication-assisted treatment (MOUD) options after methadone, with a substantial prescription base.
• Globally, market growth is supported by expanding treatment programs, generic adoption, and national opioid crisis policies—but exact totals vary by how analysts define the “buprenorphine/naloxone” segment.

One clarifying question

Do you want the global or US revenue market size for buprenorphine/naloxone—and for which year (e.g., 2023)?